China Pharma Holdings (CPHI) Shares are Up 15.11%

China Pharma Holdings (CPHI) : Traders are bullish on China Pharma Holdings (CPHI) as it has outperformed the S&P 500 by a margin of 6.99% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 14.4%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 15.11% in the last 1 week, and is up 14.22% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

China Pharma Holdings (NYSEMKT:CPHI): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.26 and $0.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.30, notching a gain of 14.09% for the day. The total traded volume was 1,214,738 . The stock had closed at $0.26 on the previous day.


The stock has recorded a 20-day Moving Average of 18.32% and the 50-Day Moving Average is 22.89%. China Pharma Holdings, Inc. is up 48.2% in the last 3-month period. Year-to-Date the stock performance stands at 85.25%.

China Pharma Holdings, Inc. is a holding company, which conducts all of its production, marketing, finance, development and administrative activities through its wholly owned subsidiary located in the Peoples Republic of China (the PRC). The Company is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of diseases and medical conditions in the PRC. Its operations are conducted in the PRC, where its manufacturing facilities are located. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. All of its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). It offers products for central nervous system (CNS) and cerebral-cardiovascular diseases, anti-infection and respiratory diseases, digestive diseases and others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.